tetano
Editor, Senior Moderator
Viruses. 2018 Jan 21;10(1). pii: E48. doi: 10.3390/v10010048.
[h=1]Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.[/h] Pickens JA[SUP]1[/SUP], Tripp RA[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Two primary causes of respiratory tract infections are respiratory syncytial virus (RSV) and influenza viruses, both of which remain major public health concerns. There are a limited number of antiviral drugs available for the treatment of RSV and influenza, each having limited effectiveness and each driving selective pressure for the emergence of drug-resistant viruses. Novel broad-spectrum antivirals are needed to circumvent problems with current disease intervention strategies, while improving the cytokine-induced immunopathology associated with RSV and influenza infections. In this review, we examine the use of Verdinexor (KPT-335, a novel orally bioavailable drug that functions as a selective inhibitor of nuclear export, SINE), as an antiviral with multifaceted therapeutic potential. KPT-335 works to (1) block CRM1 (i.e., Chromosome Region Maintenance 1; exportin 1 or XPO1) mediated export of viral proteins critical for RSV and influenza pathogenesis; and (2) repress nuclear factor κB (NF-κB) activation, thus reducing cytokine production and eliminating virus-associated immunopathology. The repurposing of SINE compounds as antivirals shows promise not only against RSV and influenza virus but also against other viruses that exploit the nucleus as part of their viral life cycle.
[h=4]KEYWORDS:[/h] Chromosome Region Maintenance 1; Influenza; KPT-335; Respiratory syncytial virus; Verdinexor; antiviral
PMID: 29361733 DOI: 10.3390/v10010048
Free full text
[h=1]Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.[/h] Pickens JA[SUP]1[/SUP], Tripp RA[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Two primary causes of respiratory tract infections are respiratory syncytial virus (RSV) and influenza viruses, both of which remain major public health concerns. There are a limited number of antiviral drugs available for the treatment of RSV and influenza, each having limited effectiveness and each driving selective pressure for the emergence of drug-resistant viruses. Novel broad-spectrum antivirals are needed to circumvent problems with current disease intervention strategies, while improving the cytokine-induced immunopathology associated with RSV and influenza infections. In this review, we examine the use of Verdinexor (KPT-335, a novel orally bioavailable drug that functions as a selective inhibitor of nuclear export, SINE), as an antiviral with multifaceted therapeutic potential. KPT-335 works to (1) block CRM1 (i.e., Chromosome Region Maintenance 1; exportin 1 or XPO1) mediated export of viral proteins critical for RSV and influenza pathogenesis; and (2) repress nuclear factor κB (NF-κB) activation, thus reducing cytokine production and eliminating virus-associated immunopathology. The repurposing of SINE compounds as antivirals shows promise not only against RSV and influenza virus but also against other viruses that exploit the nucleus as part of their viral life cycle.
[h=4]KEYWORDS:[/h] Chromosome Region Maintenance 1; Influenza; KPT-335; Respiratory syncytial virus; Verdinexor; antiviral
PMID: 29361733 DOI: 10.3390/v10010048
Free full text